Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 976-983

  Alavi, Maryam ^a   Spelman, Tim ^b   Matthews, Gail V ^a   Haber, Paul S ^c,i   Day, Carolyn ^a,c   van Beek, Ingrid ^d   Walsh, Nick ^e   Yeung, Barbara ^a   Bruneau, Julie ^f   Petoumenos, Kathy ^a   Dolan, Kate ^g,h   Kaldor, John ^a   Dore, Gregory J ^a,o   Hellard, Margaret ^b,p   Grebely, Jason ^a   Acraman, Brian ^a   Amin, Janaki ^a   Doab, Anna ^a   Carroll, Therese ^a   Teutsch, Suzy ^h   Li, Hui ^h   Oon, Alieen ^h   Cameron, Barbara ^h   Lloyd, Andrew ^h   White, Peter ^h   Rawlinson, William ^h,n   Goy, Kylie ^b   Nguyen, Oanh ^b   von Bibra, Sally ^b   Ffrench, Rose ^b   McCaughan, Geoff ⁱ   Madden, Annie ^j   Farrell, Geoff ^k   Crofts, Nick ^l   Sievert, William ^m   Baker, David ^d   Jacka, Brendan ^o   Pan, Yong ^o   Shaw, David ^q   Sasadeusz, Joe ^r   Crawford, Darrell ^s   Phung, Nghi ^t   George, Jacob ^u   Bloch, Mark ^v   Hughes, Brian ^w   Mollison, Lindsay ^x   Roberts, Stuart ^p   Desmond, Paul ^y   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Monash University ^*  (Australia)

^e MONASH UNIVERSITY   (Australia)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^j Australian Injecting and Illicit Drug Users League   (Australia)

^k CANBERRA HOSPITAL   (Australia)

^l Nossal Institute   (Australia)

^m MONASH MEDICAL CENTRE   (Australia)

ⁿ SEALS   (Australia)

^o ST VINCENT S HOSPITAL   (Australia)

^p ALFRED HOSPITAL   (Australia)

^q ROYAL ADELAIDE HOSPITAL   (Australia)

^r ROYAL MELBOURNE HOSPITAL   (Australia)

^s PRINCESS ALEXANDRA HOSPITAL   (Australia)

^t NEPEAN HOSPITAL   (Australia)

^u WESTMEAD HOSPITAL   (Australia)

^v Holdsworth House GP Practice   (Australia)

^w JOHN HUNTER HOSPITAL   (Australia)

^x FREMANTLE HOSPITAL   (Australia)

^y ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

Antiviral therapy; HCV; Injecting drug use; People who inject drugs

Indexed keywords

DIAMORPHINE; METHAMPHETAMINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGE; ARTICLE; AUSTRALIA; BEHAVIOR CHANGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMPLOYMENT STATUS; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INJECTING RISK BEHAVIOR; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIXED INFECTION; MULTICENTER STUDY; NEEDLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEX RATIO; SOCIAL STATUS; SYRINGE; TREATMENT DURATION; CLINICAL TRIAL; COMPLICATION; DRUG USE; NEEDLE SHARING; ODDS RATIO; PATIENT DROPOUT; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; NEEDLE SHARING; ODDS RATIO; PATIENT DROPOUTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84941811804     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.05.003     Document Type: Article

References (42)

1. Alavi M., Raffa J.D., Deans G.D., Lai C., Krajden M., Dore G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 2014, 34(8):1198-1206.
2. Lawrinson P., Copeland J., Indig D. The brief treatment outcome measure: Opioid maintenance pharmacotherapy (btom), manual. Technical Report Number 156 2003 [cited September 2014], National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Available from: http://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/TR.156.PDF.
3. European Association for the Study of the Liver EASL clinical practice guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011, 55(2):245-264.
4. Aspinall E.J., Corson S., Doyle J.S., Grebely J., Hutchinson S.J., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(Suppl. 2):S80-S89.
5. Bruneau J., Brogly S.B., Tyndall M.W., Lamothe F., Franco E.L. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: The interface with social factors and service utilization. Addiction 2004, 99(6):727-737.
6. Cox J., Maurais E., Hu L., Moodie E.E., Law S., Bozinoff N., et al. Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. Drug and Alcohol Dependence 2014, 137:121-128.
7. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: The Opiate Treatment Index. British Journal of Addiction 1992, 87(5):733-742.
8. Debeck K., Kerr T., Marshall B.D., Simo A., Montaner J., Wood E. Risk factors for progression to regular injection drug use among street-involved youth in a Canadian setting. Drug and Alcohol Dependence 2013, 133(2):468-472.
9. Dimova R.B., Zeremski M., Jacobson I.M., Hagan H., Des Jarlais D.C., Talal A.H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2013, 56(6):806-816.
10. Dore G.J., Feld J.J. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin Infect Dis. 2015, 60(12):1829-1836. 10.1093/cid/civ197.
11. Dore G.J., Grebely J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31(4):331-339.
12. Dore G.J., Hellard M., Matthews G.V., Grebely J., Haber P.S., Petoumenos K., et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138(1):123-135.
13. Evans J.L., Hahn J.A., Lum P.J., Stein E.S., Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug and Alcohol Dependence 2009, 101(3):152-157.
14. Evans J.L., Hahn J.A., Page-Shafer M.K., Lum M.P.J., Stein M.E.S., Davidson M.P.J., et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). Journal of Urban Health 2003, 80(1):137-146.
15. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American association for the study of liver D, diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49(4):1335-1374.
16. Grady B.P., Schinkel J., Thomas X.V., Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clinical Infectious Diseases 2013, 57(Suppl. 2):S105-S110.
17. Grebely J., Dore G.J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72.
18. Grebely J., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015, 26:1028-1038.
19. Grebely J., Oser M., Taylor L.E., Dore G.J. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. Journal of Infectious Diseases 2013, 207(Suppl. 1):S19-S25.
20. Grebely J., Petoumenos K., Matthews G., Haber P., Marks P., Lloyd A., et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC study. Drug and Alcohol Dependence 2010, 107(2):244-249.
21. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 2009, 16(5):352-358.
22. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology 2013, 10(9):553-562.
23. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
24. Horyniak D., Dietze P., Degenhardt L., Higgs P., McIlwraith F., Alati R., et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug and Alcohol Dependence 2013, 132(3):541-546.
25. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. Journal of Viral Hepatitis 2014, 21(3):198-207.
26. Linton S.L., Celentano D.D., Kirk G.D., Mehta S.H. The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. Drug and Alcohol Dependence 2013, 132(3):457-465.
27. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101(10):1499-1508.
28. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40(1):120-124.
29. Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 2008, 33(3):126-133.
30. Myles A., Mugford G.J., Zhao J., Krahn M., Wang P.P. Physicians' attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a national specialist survey in Canada. Canadian Journal of Gastroenterology 2011, 25(3):135-139.
31. National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2005-2009. [cited September 2014]. Available from: http://kirby.unsw.edu.au/sites/default/files/hiv/resources/ANS.%202005_2009.pdf.
32. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews [Review]. Lancet 2011, 378(9791):571-583.
33. Newman A.I., Beckstead S., Beking D., Finch S., Knorr T., Lynch C., et al. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Canadian Journal of Gastroenterology 2013, 27(4):217.
34. Pouget E.R., Hagan H., Des Jarlais D.C. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012, 107(6):1057-1065.
35. Reed C., Bliss C., Stuver S.O., Heeren T., Tumilty S., Horsburgh C.R., et al. Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. American Journal of Public Health 2013, 103(1):105-111.
36. Robaeys G., Grebely J., Mauss S., Bruggmann P., Moussalli J., De Gottardi A., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clinical Infectious Diseases 2013, 57(Suppl. 2):S129-S137.
37. Sasadeusz J.J., Dore G., Kronborg I., Barton D., Yoshihara M., Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011, 106(5):977-984.
38. Schaefer M., Sarkar R., Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clinical Infectious Diseases 2013, 57(Suppl. 2):S111-S117.
39. Shah N.G., Galai N., Celentano D.D., Vlahov D., Strathdee S.A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug and Alcohol Dependence 2006, 83(2):147-156.
40. Subramaniam G.A., Stitzer M.L., Woody G., Fishman M.J., Kolodner K. Clinical characteristics of treatment-seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug and Alcohol Dependence 2009, 99(1):141-149.
41. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 2011, 106(11):1978-1988.
42. Van Thiel D.H., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. The American Journal of Gastroenterology 2003, 98(10):2281-2288.